Ponesimod for the treatment of relapsing-remitting multiple sclerosis

Abstract

Gone are the days when neurologists considering disease modifying therapy for their patients with relapsing remitting multiple sclerosis (RRMS) could only access a handful of agents that are easy to compare. This charmingly simple situation has rapidly evolved to an increased ability to access a variety of agents that are potentially suitable for the equally complex spectrum of RRMS syndromes with different clinical and radiological features. The approval of ponesimod by NICE as a first- or second-line treatment for RRMS is another welcomed addition to the current agents available.